BidaskClub upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a hold rating to a buy rating in a research note released on Friday morning.

Several other equities analysts have also issued reports on the company. Wedbush restated an outperform rating and set a $19.00 price target on shares of Fate Therapeutics in a research note on Tuesday. HC Wainwright restated a hold rating and set a $12.00 price target on shares of Fate Therapeutics in a research note on Tuesday. Zacks Investment Research upgraded Fate Therapeutics from a sell rating to a hold rating in a research note on Monday, August 6th. Citigroup began coverage on Fate Therapeutics in a research note on Wednesday, August 1st. They set a buy rating and a $20.00 price target on the stock. Finally, ValuEngine upgraded Fate Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday, May 2nd. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Fate Therapeutics has an average rating of Buy and a consensus target price of $15.63.

Fate Therapeutics traded up $0.08, hitting $11.50, on Friday, according to Marketbeat Ratings. 320,353 shares of the stock traded hands, compared to its average volume of 474,248. Fate Therapeutics has a 52 week low of $2.81 and a 52 week high of $14.45. The company has a quick ratio of 7.20, a current ratio of 4.92 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $612.18 million, a price-to-earnings ratio of -11.27 and a beta of 1.57.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Fate Therapeutics had a negative net margin of 1,387.53% and a negative return on equity of 95.07%. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts expect that Fate Therapeutics will post -1.21 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in FATE. Wells Fargo & Company MN grew its stake in shares of Fate Therapeutics by 34.6% in the 4th quarter. Wells Fargo & Company MN now owns 328,023 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 84,269 shares during the period. BlackRock Inc. grew its stake in shares of Fate Therapeutics by 2.6% in the 4th quarter. BlackRock Inc. now owns 1,705,293 shares of the biopharmaceutical company’s stock valued at $10,421,000 after purchasing an additional 43,499 shares during the period. Geode Capital Management LLC grew its stake in shares of Fate Therapeutics by 14.9% in the 4th quarter. Geode Capital Management LLC now owns 347,573 shares of the biopharmaceutical company’s stock valued at $2,123,000 after purchasing an additional 45,142 shares during the period. Deutsche Bank AG grew its stake in shares of Fate Therapeutics by 146.5% in the 4th quarter. Deutsche Bank AG now owns 86,531 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 51,433 shares during the period. Finally, Two Sigma Advisers LP grew its stake in shares of Fate Therapeutics by 257.0% in the 4th quarter. Two Sigma Advisers LP now owns 71,400 shares of the biopharmaceutical company’s stock valued at $436,000 after purchasing an additional 51,400 shares during the period. Institutional investors own 74.52% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Featured Story: Dividend Stocks – Are They Right For You?

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.